NasdaqGS:ACADBiotechs
Why ACADIA Pharmaceuticals (ACAD) Is Up 17.1% After EMA Backs DAYBU For Rett Syndrome
Acadia Pharmaceuticals recently reported that the EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion, after re-examination, recommending EU marketing authorization for DAYBU (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in patients aged five years and older.
If the European Commission confirms this opinion, DAYBU would become the first approved therapy for Rett syndrome in the EU, potentially reshaping care for a severely underserved rare...